In this issue:
Venetoclax + low-dose cytarabine for AML
Ibrutinib + R-CHOP in non-GCB DLBCL
Bendamustine + rituximab vs R-CHOP or R-CVP in NHL or MCL
Brentuximab vedotin and ESHAP for Hodgkin lymphoma
Lenalidomide + rituximab in CNS or intraocular lymphoma
Rituximab + polatuzumab vedotin or pinatuzumab vedotin in NHL
BCR-ABL1 kinase domain mutations identified by NGS in CML
Surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Long-term follow-up of RESONATE: ibrutinib vs ofatumumab
Sequential bendamustine, ibrutinib and obinutuzumab in CLL
Please login below to download this issue (PDF)